EMA Authorised: Tuznue (trastuzumab) — Prestige Biopharma Belgium

View source ↗

Summary

The European Medicines Agency authorised Tuznue (trastuzumab) from Prestige Biopharma Belgium for breast cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tuznue (trastuzumab)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Prestige Biopharma Belgium. Decision date: 23/10/2025